Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly(ADP-ribose)polymerase(PARP)inhibitors  

作　　者：Chaowen Shi Dewan Ren Yufeng Gao Ya-Mei Dang Zhigang Tu Hanqing Liu 

机构地区：[1]School of Life Sciences,Jiangsu University,Zhenjiang,Jiangsu 212013,China [2]School of Pharmacy,Jiangsu University,Zhenjiang,Jiangsu 212013,China [3]Department of Pathology,Gansu Provincial Hospital,Lanzhou,Gansu 730000,China

出　　处：《Genes & Diseases》2023年第5期1791-1794,共4页基因与疾病（英文）

基　　金：supported by the National Natural Science Foundation of China(No.81672582 to HL,31771521 to ZT,and 82200083 to CS),Top Talent of Innovative Research Team of Jiangsu Province,China(to HL and ZT);the Natural Science Foundation of Jiangsu Province,China(No.BK20200891 to CS);the Senior Talent Start-up Funds of Jiangsu University(China)(No.14JDG050 and 14JDG011 to HL and ZT).

摘　　要：Mantle cell lymphoma(MCL)is an aggressive subtype of non-Hodgkin lymphoma(NHL)characterized by the overexpression of cyclin D1 and deregulated cell cycle.1 Ganetespib(STA-9090),a second-generation HSP90 inhibitor,dramatically disrupted oncogenic cellular processes resulting in the inhibition of client protein-derived tumors in preclinical studies.2 The synthetic lethal strategy using poly(ADP-ribose)polymerase(PARP)inhibitors(PARPis)has been reported as a powerful therapeutic intervention in MCL and their effectiveness can be increased by a deficiency in DNA damage repair(DDR),especially homologous recombination deficiency.3 Since we found earlier that transient ganetespib treatment can induce defects in DDR,we hypothesized that ganetespib treatment can possibly enhance the sensitivity of MCL cells to PARPis and HSP90 and PARP is can be demonstrated as promising combination therapies for MCL.

关 键 词：LYMPHOMA PARP sized 

分 类 号：R73[医药卫生—肿瘤]